

Special Issue

Antimicrobial Resistance and Infection Control

Message from the Guest Editor

Antimicrobial resistance (AMR) is recognized by the World Health Organization as a priority, one of the top ten global public health threats facing humanity—even in the face of the worldwide challenge of the COVID-19 pandemic. Although AMR is a problem, it is not an unmanageable problem; indeed, between 2014 and 2017, the use of antibiotics in people dropped down by 7.3% at least in the UK. According to the WHO, the overuse of medicines in humans, livestock, and agriculture, as well as poor access to clean water, sanitation, and hygiene are some of the factors that have accelerated the AMR threat worldwide. Without effective antibiotics, the success of modern medicine in treating infections, including antimicrobial therapy during major surgery and cancer chemotherapy, would be at increased risk. The aim of this Special Issue is to gather new information of the spread of AMR in the community as well as in the hospital settings, but also to collect specific clinical experiences with new antibiotics against MDR microorganisms.

Guest Editor

Dr. Dino Sgarabotto

Policlinico di Abano, Piazza Cristoforo Colombo 1, 35031 Abano (PD), Italy

Deadline for manuscript submissions

closed (31 October 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/98794

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)